Apigenin's Therapeutic Potential Against Viral Infection

Front Biosci (Landmark Ed). 2023 Oct 17;28(10):237. doi: 10.31083/j.fbl2810237.

Abstract

Several antiviral drugs are clinically approved to treat influenza that is a highly prevalent acute respiratory disease. However, emerging drug-resistant virus strains undermine treatment efficacy, highlighting the exigency for novel antiviral drugs to counter these drug-resistant strains. Plants and their derivates have been historically utilized as medicinal remedies, and extensive studies have evidenced the antiviral potential of phytochemicals. Notably, apigenin is a predominant flavonoid with minimal toxicity and substantial therapeutic effects in various disease models. Despite its many anti-inflammatory, anti-oxidant, anti-cancer, anti-bacterial, and other beneficial bioactivities, existing reviews have yet to focus on apigenin's antiviral effects. Therefore, this review elucidates apigenin's therapeutic and antiviral properties in vitro and in vivo, discussing its mode of action and future prospects. Apigenin's remarkable inhibition by modulating multiple mechanisms against viruses has promising potential for novel plant-derived antiviral drugs and further clinical study developments.

Keywords: 4′,5,7-trihydroxyflavone; antiviral drugs; flavonoids; influenza; phytochemicals.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use
  • Apigenin / chemistry
  • Apigenin / pharmacology
  • Apigenin / therapeutic use
  • Flavonoids
  • Humans
  • Neoplasms* / drug therapy
  • Virus Diseases* / drug therapy

Substances

  • Apigenin
  • Flavonoids
  • Antiviral Agents